ARTICLE | Product Development
Novartis’ growth drivers, beyond the setbacks
From assets against BTK to BAFF-R, Swiss pharma looking ahead to other pipeline inflection points
September 10, 2026 6:52 PM UTC
A pair of negative Phase III readouts will put a dent in Novartis’ growth story, but shouldn’t derail the broader thesis for the Swiss pharma.
It hasn’t been a stellar September for Novartis AG (SIX:NOVN; NYSE:NVS), which has suffered three setbacks in the span of a week. ...
BCIQ Company Profiles